Quest Diagnostics
DGX
#1094
Rank
NZ$35.31 B
Marketcap
NZ$315.82
Share price
-0.96%
Change (1 day)
17.10%
Change (1 year)
Quest Diagnostics is an American clinical laboratory company offering access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders and employment and court ordered drug testing.

EPS for Quest Diagnostics (DGX)

EPS in 2025 (TTM): NZ$14.87

According to Quest Diagnostics 's latest financial reports the company's current EPS (TTM) is NZ$14.96. In 2024 the company made an earnings per share (EPS) of NZ$13.47 an increase over its 2023 EPS that were of NZ$13.14.

EPS history for Quest Diagnostics from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$14.8710.37%
2024NZ$13.472.5%
2023NZ$13.14-5.83%
2022NZ$13.95-49.21%
2021NZ$27.4849.72%
2020NZ$18.3566.67%
2019NZ$11.0118%
2018NZ$9.33-4.26%
2017NZ$9.7523.19%
2016NZ$7.91-7.11%
2015NZ$8.5228.46%
2014NZ$6.63-31.61%
2013NZ$9.7060.46%
2012NZ$6.04

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
LabCorp
LH
NZ$17.75 18.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Psychemedics
PMD
NZ-$1.23-108.24%๐Ÿ‡บ๐Ÿ‡ธ USA
NeoGenomics
NEO
NZ-$1.52-110.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Enzo Biochem
ENZB
NZ-$0.36-102.43%๐Ÿ‡บ๐Ÿ‡ธ USA
Qiagen
QGEN
NZ$3.24-78.37%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands